Authors

Gerard E. Heath BS, Daniel A. Hamstra MD, Dean A. Shumway MD

Latest:

Factors Influencing Patient-Reported Rectal Toxicity Following External Beam Radiation Therapy for Prostate Cancer

Developing and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.

Gerold Meinhardt, MD

Latest:

Dr. Meinhardt on the Impact of the RESORCE Study in HCC

Gerold Meinhardt, MD, global clinical leader at Bayer Pharmaceuticals, discusses the impact of the RESORCE trial in hepatocellular carcinoma.

Gerrit zur Hausen, MSc

Ghanshyam Yadav, MD

Latest:

Dr. Yadav on Differences in Type 1 and Type 2 Uterine Cancer

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.

Ghassan Abou-Alfa, MD

Latest:

Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC

Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center

Ghassan K. Abou-Alfa, MD

Latest:

Safety Profiles of Available Therapies in Advanced HCC

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center

Ghassan K. Abou-Alfa, MD, Memorial Sloan-Kettering Cancer

Latest:

Rapid Readouts: Final Results from Phase 3 ClarIDHy Trial

Ghassan K. Abou-Alfa, MD, reports on data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting regarding final results from the ClarIDHy trial. In the phase 3 study, investigators examined ivosidenib vs placebo in patients with previously treated cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation.

Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center

Ghassan K Abou-Alfa, MD, Memorial Sloan Kettering Center

Ghassan K. Abou-Alfa, MD, Weill Cornell Medical College

Ghassan K. About-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center

Ghulam Rehman Mohyuddin

Latest:

Bone Marrow Biopsy Simulation Training for Fellows

A bone marrow aspirate and biopsy is the single most common procedure that hematologists and oncologists carry out day in and day out throughout their career.

Giada Bianchi, MD

Latest:

Dr. Bianchi on Diagnostic Factors for AL Amyloidosis

Giada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.

Giancarlo Agnelli, MD

Latest:

Dr. Agnelli Discusses Apixaban for Venous Thromboembolism

Giancarlo Agnelli, MD, University of Perugia, Perugia, Italy, discusses the results of a study comparing the efficacy and safety of two doses of apixaban, an oral factor Xa inhibitor, with placebo for the treatment of venous thromboembolism.

Gilberto De Lima Lopes, MD

Latest:

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Gilberto Lopes Jr, MD

Latest:

Dr. Lopes Discusses Steroid Side Effects in Lung Cancer Management

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses steroid side effects in lung cancer management.

Gilberto Lopes, MD

Latest:

Dr Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC

Gilberto Lopes, MD, MBA, FAMS, discusses findings from a cost-effectiveness analysis of osimertinib/chemotherapy vs amivantamab/lazertinib in EGFR-mutated NSCLC.

Gilles A. Salles, MD, PhD

Latest:

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.